Azathioprine (Imuran) administration and the development of malignant lymphomas in NZB mice.
D000419:Albuminuria; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D000818:Animals; D001379:Azathioprine / Q000009:adverse effects* / Q000494:pharmacology; D003298:Coombs Test; D005921:Glomerulonephritis / Q000175:diagnosis; D006400:Hematocrit; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000139:chemically induced; D007958:Leukocyte Count; D008113:Liver Neoplasms / Q000139:chemically induced; D008175:Lung Neoplasms / Q000139:chemically induced; D008198:Lymph Nodes / Q000473:pathology; D008223:Lymphoma / Q000139:chemically induced*; D051379:Mice; D009375:Neoplasms, Glandular and Epithelial / Q000139:chemically induced; D011704:Pyelonephritis / Q000175:diagnosis; D013160:Splenic Neoplasms / Q000139:chemically induced; D013945:Thymoma / Q000139:chemically induced; D013953:Thymus Neoplasms / Q000139:chemically induced; D014508:Urea / Q000097:blood
D007166:Immunosuppressive Agents; D014508:Urea; D001379:Azathioprine